Aptose Biosciences Inc. (APS.TO)
CAD 0.27
(0.0%)
CAD 0.27
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -52.26 Million USD | -24.26% |
| 2022 | -42.06 Million USD | 35.11% |
| 2021 | -64.82 Million USD | -17.52% |
| 2020 | -55.16 Million USD | -110.14% |
| 2019 | -26.25 Million USD | 9.41% |
| 2018 | -29.02 Million USD | -149.56% |
| 2017 | -11.74 Million USD | 15.43% |
| 2016 | -14.15 Million USD | -21.0% |
| 2015 | -12.78 Million USD | 3.26% |
| 2014 | -11.72 Million USD | -33.82% |
| 2013 | -8.76 Million USD | -63.63% |
| 2012 | -5.36 Million USD | -21.16% |
| 2011 | -4.42 Million USD | 12.31% |
| 2010 | -5.04 Million USD | 67.76% |
| 2009 | -5.31 Million USD | -198.03% |
| 2008 | -6.4 Million USD | 66.93% |
| 2007 | -10.71 Million USD | -180.33% |
| 2006 | -6.53 Million USD | 53.46% |
| 2005 | -12.88 Million USD | -162.17% |
| 2004 | -15.55 Million USD | 190.75% |
| 2003 | -21.59 Million USD | -248.79% |
| 2002 | 14.49 Million USD | 288.0% |
| 2001 | -7.7 Million USD | 17.76% |
| 2000 | -9.37 Million USD | -116.77% |
| 1999 | -4.32 Million USD | -44.88% |
| 1998 | -2.98 Million USD | 3.41% |
| 1997 | -3.08 Million USD | 0.98% |
| 1996 | -3.12 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -9.65 Million USD | 19.69% |
| 2024 Q2 | -7.24 Million USD | 24.95% |
| 2023 FY | - USD | -24.26% |
| 2023 Q1 | -14.09 Million USD | -36.79% |
| 2023 Q2 | -14.33 Million USD | -1.7% |
| 2023 Q3 | -11.57 Million USD | 19.27% |
| 2023 Q4 | -12.01 Million USD | -3.85% |
| 2022 FY | - USD | 35.11% |
| 2022 Q4 | -10.3 Million USD | -4.3% |
| 2022 Q1 | -11.35 Million USD | 53.07% |
| 2022 Q2 | -10.52 Million USD | 7.24% |
| 2022 Q3 | -9.88 Million USD | 6.16% |
| 2021 Q3 | -11.2 Million USD | 15.93% |
| 2021 Q4 | -24.18 Million USD | -115.8% |
| 2021 Q2 | -13.33 Million USD | 17.19% |
| 2021 Q1 | -16.09 Million USD | -10.15% |
| 2021 FY | - USD | -17.52% |
| 2020 Q1 | -11.66 Million USD | -50.68% |
| 2020 Q2 | -15.74 Million USD | -34.99% |
| 2020 Q4 | -14.61 Million USD | -11.22% |
| 2020 Q3 | -13.14 Million USD | 16.54% |
| 2020 FY | - USD | -110.14% |
| 2019 Q3 | -6.87 Million USD | -11.14% |
| 2019 Q2 | -6.18 Million USD | -13.53% |
| 2019 Q1 | -5.44 Million USD | 13.2% |
| 2019 FY | - USD | 9.41% |
| 2019 Q4 | -7.74 Million USD | -12.58% |
| 2018 Q3 | -5.58 Million USD | 45.82% |
| 2018 FY | - USD | -149.56% |
| 2018 Q1 | -6.81 Million USD | -151.96% |
| 2018 Q2 | -10.3 Million USD | -51.29% |
| 2018 Q4 | -6.27 Million USD | -12.47% |
| 2017 Q3 | -2.76 Million USD | -11.57% |
| 2017 FY | - USD | 15.43% |
| 2017 Q1 | -3.27 Million USD | -9.91% |
| 2017 Q2 | -2.47 Million USD | 24.47% |
| 2017 Q4 | -2.7 Million USD | 2.22% |
| 2016 FY | - USD | -21.0% |
| 2016 Q4 | -2.98 Million USD | 5.0% |
| 2016 Q3 | -3.14 Million USD | 27.05% |
| 2016 Q2 | -4.3 Million USD | -15.41% |
| 2016 Q1 | -3.73 Million USD | -10.07% |
| 2015 FY | - USD | 3.26% |
| 2015 Q1 | -2.78 Million USD | 9.1% |
| 2015 Q4 | -3.38 Million USD | -17.14% |
| 2015 Q3 | -2.89 Million USD | 3.33% |
| 2015 Q2 | -2.99 Million USD | -7.3% |
| 2014 FY | - USD | -33.82% |
| 2014 Q4 | -3.06 Million USD | -79863.55% |
| 2014 Q3 | -3838.34 USD | 99.9% |
| 2014 Q2 | -3.82 Million USD | -80.53% |
| 2014 Q1 | -2.11 Million USD | 17.51% |
| 2013 FY | - USD | -63.63% |
| 2013 Q4 | -2.56 Million USD | -154.93% |
| 2013 Q2 | -1.23 Million USD | 6.84% |
| 2013 Q3 | -1 Million USD | 18.8% |
| 2013 Q1 | -1.33 Million USD | 17.61% |
| 2012 FY | - USD | -21.16% |
| 2012 Q1 | -1.01 Million USD | 28.03% |
| 2012 Q2 | -829.51 Thousand USD | 18.42% |
| 2012 Q3 | -1.26 Million USD | -52.11% |
| 2012 Q4 | -1.61 Million USD | -27.97% |
| 2011 Q2 | -1.05 Million USD | 34.4% |
| 2011 Q1 | -1.6 Million USD | -36.93% |
| 2011 Q3 | -1.13 Million USD | -7.57% |
| 2011 Q4 | -1.41 Million USD | -24.5% |
| 2011 FY | - USD | 12.31% |
| 2010 Q3 | -1.06 Million USD | 36.06% |
| 2010 FY | - USD | 67.76% |
| 2010 Q1 | -1.25 Million USD | -8.1% |
| 2010 Q2 | -1.66 Million USD | -31.99% |
| 2010 Q4 | -1.17 Million USD | -10.51% |
| 2009 FY | - USD | -198.03% |
| 2009 Q4 | -1.16 Million USD | 89.41% |
| 2009 Q3 | -11 Million USD | -747.79% |
| 2009 Q2 | -1.29 Million USD | -9.52% |
| 2009 Q1 | -1.18 Million USD | -10.78% |
| 2008 Q1 | -3.06 Million USD | -22.76% |
| 2008 Q2 | -9.1 Million USD | -197.48% |
| 2008 FY | - USD | 66.93% |
| 2008 Q3 | -2.05 Million USD | 77.43% |
| 2008 Q4 | -1.07 Million USD | 47.91% |
| 2007 Q1 | -1.14 Million USD | 40.15% |
| 2007 Q4 | -2.49 Million USD | 64.53% |
| 2007 Q3 | -7.02 Million USD | -449.94% |
| 2007 Q2 | -1.27 Million USD | -11.43% |
| 2007 FY | - USD | -180.33% |
| 2006 Q1 | -2.61 Million USD | 25.12% |
| 2006 FY | - USD | 53.46% |
| 2006 Q4 | -1.91 Million USD | -30.89% |
| 2006 Q3 | -1.46 Million USD | 16.84% |
| 2006 Q2 | -1.76 Million USD | 32.69% |
| 2005 Q2 | 32.21 Million USD | 987.58% |
| 2005 Q1 | -3.62 Million USD | 18.3% |
| 2005 Q4 | -3.49 Million USD | 12.55% |
| 2005 Q3 | -3.99 Million USD | -112.4% |
| 2005 FY | - USD | -162.17% |
| 2004 Q2 | -5.28 Million USD | 11.24% |
| 2004 Q4 | -4.44 Million USD | 0.25% |
| 2004 Q3 | -4.45 Million USD | 15.74% |
| 2004 Q1 | -5.95 Million USD | -34.68% |
| 2004 FY | - USD | 190.75% |
| 2003 Q3 | -5.8 Million USD | -221.78% |
| 2003 Q4 | -4.42 Million USD | 23.8% |
| 2003 Q2 | 4.76 Million USD | 47.88% |
| 2003 Q1 | 3.22 Million USD | 236.75% |
| 2003 FY | - USD | -248.79% |
| 2002 Q4 | -2.35 Million USD | 6.24% |
| 2002 FY | - USD | 288.0% |
| 2002 Q1 | -1.1 Million USD | 52.68% |
| 2002 Q2 | -2.3 Million USD | -108.87% |
| 2002 Q3 | -2.51 Million USD | -8.78% |
| 2001 Q4 | -2.33 Million USD | -31.01% |
| 2001 FY | - USD | 17.76% |
| 2001 Q3 | -1.78 Million USD | 53.72% |
| 2001 Q2 | -3.85 Million USD | -135.68% |
| 2001 Q1 | -1.63 Million USD | 29.25% |
| 2000 Q1 | -823.96 Thousand USD | -51.95% |
| 2000 Q3 | -1.63 Million USD | 33.45% |
| 2000 FY | - USD | -116.77% |
| 2000 Q2 | -2.46 Million USD | -198.89% |
| 2000 Q4 | -2.31 Million USD | -41.04% |
| 1999 Q2 | -596.07 Thousand USD | 59.8% |
| 1999 Q1 | -726.82 Thousand USD | -69.83% |
| 1999 Q4 | -542.27 Thousand USD | -102.62% |
| 1999 FY | - USD | -44.88% |
| 1999 Q3 | -267.63 Thousand USD | 32.88% |
| 1998 Q1 | -702.64 Thousand USD | 6.68% |
| 1998 Q2 | -349.08 Thousand USD | 64.51% |
| 1998 Q4 | -584.1 Thousand USD | 28.99% |
| 1998 Q3 | -822.57 Thousand USD | -135.64% |
| 1998 FY | - USD | 3.41% |
| 1997 Q4 | -702.74 Thousand USD | -62.68% |
| 1997 Q3 | -647.94 Thousand USD | 0.0% |
| 1997 FY | - USD | 0.98% |
| 1996 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Appili Therapeutics Inc. | -2.09 Million CAD | -2393.254% |
| Eupraxia Pharmaceuticals Inc. | -37.39 Million CAD | -39.771% |
| Helix BioPharma Corp. | -9.38 Million CAD | -456.694% |
| Microbix Biosystems Inc. | 1.95 Million CAD | 2770.735% |
| Medicenna Therapeutics Corp. | -18.67 Million CAD | -179.957% |
| Satellos Bioscience Inc. | -15.7 Million CAD | -232.811% |
| Oncolytics Biotech Inc. | -33.71 Million CAD | -55.052% |
| Sernova Corp. | -40.19 Million CAD | -30.042% |